155 related articles for article (PubMed ID: 35042970)
1. Functional characterization of NPM1-TYK2 fusion oncogene.
Kuravi S; Baker RW; Mushtaq MU; Saadi I; Lin TL; Vivian CJ; Valluripalli A; Abhyankar S; Ganguly S; Cui W; Elenitoba-Johnson KSJ; Welch DR; Jensen RA; Saunthararajah Y; McGuirk JP; Balusu R
NPJ Precis Oncol; 2022 Jan; 6(1):3. PubMed ID: 35042970
[TBL] [Abstract][Full Text] [Related]
2. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.
Velusamy T; Kiel MJ; Sahasrabuddhe AA; Rolland D; Dixon CA; Bailey NG; Betz BL; Brown NA; Hristov AC; Wilcox RA; Miranda RN; Medeiros LJ; Jeon YK; Inamdar KV; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Dec; 124(25):3768-71. PubMed ID: 25349176
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.
Kuravi S; Cheng J; Fangman G; Polireddy K; McCormick S; Lin TL; Singh AK; Abhyankar S; Ganguly S; Welch DR; Jensen RA; McGuirk JP; Balusu R
Mol Cancer Res; 2021 May; 19(5):913-920. PubMed ID: 33514657
[TBL] [Abstract][Full Text] [Related]
4. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
van der Krogt JA; Bempt MV; Ferreiro JF; Mentens N; Jacobs K; Pluys U; Doms K; Geerdens E; Uyttebroeck A; Pierre P; Michaux L; Devos T; Vandenberghe P; Tousseyn T; Cools J; Wlodarska I
Haematologica; 2017 Sep; 102(9):1605-1616. PubMed ID: 28659337
[TBL] [Abstract][Full Text] [Related]
6. Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease.
Lawrence K; Berry B; Handshoe J; Hout D; Mazzola R; Morris SW; Saltman DL
BMC Res Notes; 2015 Jul; 8():308. PubMed ID: 26187744
[TBL] [Abstract][Full Text] [Related]
7. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.
Ma Z; Cools J; Marynen P; Cui X; Siebert R; Gesk S; Schlegelberger B; Peeters B; De Wolf-Peeters C; Wlodarska I; Morris SW
Blood; 2000 Mar; 95(6):2144-9. PubMed ID: 10706887
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the t(2;5) (p23;q35) translocation in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
Wood GS
Leuk Lymphoma; 1998 Mar; 29(1-2):93-101. PubMed ID: 9638979
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of nucleophosmin 1 suppresses colorectal cancer tumor growth of patient -derived xenografts via activation of p53 and inhibition of AKT.
Yu ACY; Chern YJ; Zhang P; Pasiliao CC; Rahman M; Chang G; Ren J; Tai IT
Cancer Biol Ther; 2021 Feb; 22(2):112-123. PubMed ID: 33446037
[TBL] [Abstract][Full Text] [Related]
10. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
Wood GS; Hardman DL; Boni R; Dummer R; Kim YH; Smoller BR; Takeshita M; Kikuchi M; Burg G
Blood; 1996 Sep; 88(5):1765-70. PubMed ID: 8781433
[TBL] [Abstract][Full Text] [Related]
11. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
Falini B; Nicoletti I; Bolli N; Martelli MP; Liso A; Gorello P; Mandelli F; Mecucci C; Martelli MF
Haematologica; 2007 Apr; 92(4):519-32. PubMed ID: 17488663
[TBL] [Abstract][Full Text] [Related]
12. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT
Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820
[TBL] [Abstract][Full Text] [Related]
13. Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.
Lu H; Villafane N; Dogruluk T; Grzeskowiak CL; Kong K; Tsang YH; Zagorodna O; Pantazi A; Yang L; Neill NJ; Kim YW; Creighton CJ; Verhaak RG; Mills GB; Park PJ; Kucherlapati R; Scott KL
Cancer Res; 2017 Jul; 77(13):3502-3512. PubMed ID: 28512244
[TBL] [Abstract][Full Text] [Related]
14. Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia.
Chen Y; Hu J
Ther Adv Hematol; 2020; 11():2040620719899818. PubMed ID: 32071709
[TBL] [Abstract][Full Text] [Related]
15. Definition of the interferon-alpha receptor-binding domain on the TYK2 kinase.
Yan H; Piazza F; Krishnan K; Pine R; Krolewski JJ
J Biol Chem; 1998 Feb; 273(7):4046-51. PubMed ID: 9461596
[TBL] [Abstract][Full Text] [Related]
16. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
17. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of an alpha interferon receptor 1 subunit (IFNaR1) domain required for TYK2 binding and signal transduction.
Yan H; Krishnan K; Lim JT; Contillo LG; Krolewski JJ
Mol Cell Biol; 1996 May; 16(5):2074-82. PubMed ID: 8628273
[TBL] [Abstract][Full Text] [Related]
19. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
[TBL] [Abstract][Full Text] [Related]
20. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
